{
  "ticker": "JNJ",
  "target_date": "2025-01-10",
  "actual_date": "2025-01-10",
  "collected_at": "2025-12-08T11:15:45.614746",
  "price": {
    "open": 136.81,
    "high": 139.4,
    "low": 136.5,
    "close": 137.84059143066406,
    "volume": 8821500,
    "change_1d_pct": -0.15,
    "change_7d_pct": -0.89,
    "change_30d_pct": -8.08
  },
  "technicals": {
    "rsi_14": 41.19,
    "sma_20": 140.44,
    "sma_50": 145.77,
    "macd": -1.99,
    "macd_signal": -2.122,
    "macd_histogram": 0.132,
    "bb_upper": 143.11,
    "bb_lower": 137.76,
    "price_vs_sma20_pct": -1.85,
    "price_vs_sma50_pct": -5.44,
    "volume_ratio": 1.06
  },
  "fundamentals": {
    "market_cap": 488918253568,
    "pe_ratio": 19.587837,
    "forward_pe": 19.144339,
    "price_to_book": 6.159286,
    "price_to_sales": 5.305736,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.35,
    "pct_from_52w_low": 44.25
  },
  "macro": {
    "spy": {
      "price": 575.45,
      "change_1d_pct": -1.53,
      "change_7d_pct": -0.95
    },
    "vix": {
      "level": 19.54,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.78
    },
    "dollar_index": {
      "level": 109.65
    },
    "gold": {
      "price": 2708.5
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "A First Take On CG Oncology",
      "source": "SeekingAlpha",
      "datetime": 1736528174,
      "summary": "CG Oncology's stock has dropped 40% since its IPO peak, driven by profit-taking and competitive concerns despite promising Phase 3 data for Cretostimogene. Learn more on CGON stock here.",
      "url": "https://finnhub.io/api/news?id=1a6cc91e0715e5e770fc0e23f70a2b35b26914926f44eecb335d62f79b4b39ba"
    },
    {
      "headline": "Johnson & Johnson stock outperforms competitors despite losses on the day",
      "source": "MarketWatch",
      "datetime": 1736526720,
      "summary": "Johnson & Johnson stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=3a40e13c89682c41f6b9401ae7498df4df4a03772443cfeaea0d3bf33825b068"
    },
    {
      "headline": "4 Top Dividend Growth Stocks to Build Your Portfolio Around in 2025",
      "source": "Yahoo",
      "datetime": 1736517600,
      "summary": "These companies have track records of success, increasing dividends, and fantastic growth prospects, making them all ideal portfolio anchor stocks for a long-term investor.",
      "url": "https://finnhub.io/api/news?id=fb725990662e539a6f7031711ea8aa58c87bab073cf24e1405561494be953ab8"
    },
    {
      "headline": "FDA Accepts J&J's Filing for Autoimmune Disease Drug Nipocalimab",
      "source": "Yahoo",
      "datetime": 1736515440,
      "summary": "JNJ's filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.",
      "url": "https://finnhub.io/api/news?id=eb2efdeedf1390cd72566f8fd3d2da199e314d2dc79fc0cb6e63f7ee8fa9d2ba"
    },
    {
      "headline": "Johnson & Johnson : MedTech Announces CE Mark Approval for Dual Energy THERMOCOOL SMARTTOUCH\u2122 SF Catheter",
      "source": "Finnhub",
      "datetime": 1736506929,
      "summary": "Media contact: Diane Pressman Dpressm1@its.jnj.com Anna Loring Aloring1@its.jnj.com ...",
      "url": "https://finnhub.io/api/news?id=1791a570c717d0ecbe613c12d5d80c23ff2f04be7839e0521343e326e992f241"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2024-12-12",
      "description": "xslF345X05/wk-form4_1734042449.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000106/xslF345X05/wk-form4_1734042449.xml"
    },
    {
      "form": "4",
      "date": "2024-12-12",
      "description": "xslF345X05/wk-form4_1734041779.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000104/xslF345X05/wk-form4_1734041779.xml"
    },
    {
      "form": "4",
      "date": "2024-12-12",
      "description": "xslF345X05/wk-form4_1734041373.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000102/xslF345X05/wk-form4_1734041373.xml"
    },
    {
      "form": "13F-HR",
      "date": "2024-11-13",
      "description": "xslForm13F_X02/primary_doc.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000090445424000604/xslForm13F_X02/primary_doc.xml"
    },
    {
      "form": "10-Q",
      "date": "2024-10-23",
      "description": "jnj-20240929.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000096/jnj-20240929.htm"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}